Securing Maryland-Based Drug-Substance Facility and Existing Commercial Orders to Scale the Group’s Integrated Technology Platform HONG KONG SAR – Media OutReach Newswire – 12 May 2026 – Bora Pharmaceuticals (“Bora” or “Bora Group”; TWSE: 6472; OTCQX: BORAY) today announced that...

Board Proposed NT$10 Cash Dividend Per Share HONG KONG SAR – Media OutReach Newswire – 11 March 2026 – Bora Pharmaceuticals (“Bora”; TWSE: 6472; OTCQX: BORAY) today announced its financial results and operational highlights for full year 2025 and provides...

Bora to discuss a recent collaboration with Therapi AI, highlighting its focus on strengthening operational execution across the biopharma development cycle and supply chain through AI-enabled technologies HONG KONG SAR – Media OutReach Newswire – 9 February 2026 – Bora...

Strategic realignment powering Bora’s dual-engine businesses model HONG KONG SAR – Media OutReach Newswire – 13 November 2025 – Bora Pharmaceuticals (TWSE: 6472) today announced its financial results and operational highlights for third quarter of 2025. Quarterly Business and Financial...

Positioned to Unlock M&A Value through U.S. Manufacturing Amidst Geopolitical Complexities and Specialty Portfolio HONG KONG SAR – Media OutReach Newswire – 14 May 2025 – Bora Pharmaceuticals (TWSE: 6472) today announced its financial results and operational highlights for first...